10 most important studies of olanzapine you need to know Review article
Article Sidebar
Main Article Content
Abstract
Olanzapine is one of the most important atypical antipsychotics. It is indicated as the first-line, registered psychiatric treatment for many disorders. Intensive research has led to the fact that olanzapine has achieved the highest number of approved indications. Olanzapine is indicated for acute and maintenance therapy of schizophrenia, bipolar manic and mixed episodes, bipolar depressive episodes and for the maintenance treatment of bipolar disorder. It is also indicated for treatment-resistant unipolar depression. There are also lots of off-label indications for olanzapine, like delusional disorders, anxiety disorders, post-traumatic stress disorders, eating disorders, personality disorders – especially borderline type, Tourette syndrome, behavioral and psychological symptoms of dementia, and many others, mostly behavioral disorders. Large studies found that olanzapine was better at controlling psychopathological symptoms because patients were more likely to remain on olanzapine than the other drugs. This paper presents the review of cutting-edge research works about olanzapine.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Tiihonen J, Lönnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374(9690): 620-627.
3. Karagianis J, Novick D, Pecenak J, Haro JM et al. Worldwide- Schizophrenia Outpatient Health Outcomes (W-SOHO): Baseline Characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 2009; 63(11): 1578-1588.
4. Dossenbach M, Erol A, el Mahfoud Kessaci M et al. IC-SOHO Study Group. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004; 65(3): 312-321.
5. Komossa K, Rummel-Kluge C, Hunger H et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010 Mar 17 [doi: 10.1002/14651858.CD006654.pub2].
6. McGlashan TH, Zipursky RB, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163(5): 790-799.
7. Kahn RS, Fleischhacker WW, Boter H et al. EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371(9618): 1085-1097.
8. Tiihonen J, Haukka J, Taylor M et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011; 168(6): 603-609.
9. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088.
10. Schulz SC, Zanarini MC, Bateman A et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry 2008; 193(6): 485-492.
11. Arranz B, San L, Dueñas RM et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol 2007; 22(1): 11-15.